Drug intelligence / Profile preview

rupioprostenone

Development stage: Preclinical
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Ophthalmic

Overview

Rupioprostenone is a synthetic prostaglandin F2α analog under development for ophthalmic use, specifically as an intraocular pressure-lowering agent in the treatment of glaucoma and ocular hypertension. It acts primarily by increasing uveoscleral outflow, similar to other prostaglandin analogs. Rupioprostenone is structurally related to other drugs in the prostaglandin class but may offer improved pharmacokinetic or safety profiles. As of now, it remains investigational with limited publicly available clinical data.

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on rupioprostenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rupioprostenone.

Explore the full profile